Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Feb 2021 Results published in the Clinical Cancer Research
11 Dec 2018 According to an OncoSec Medical media release, a subset of patients that completed a single cycle of TAVO in this study, were sequentially treated with nivolumab. One of these patients continues to be treated with TAVO under a compassionate use protocol.
11 Dec 2018 According to an OncoSec Medical media release, data from this study were presented at the 2018 San Antonio Breast Cancer Symposium (SABCS).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com